🔗 Permalink

Inventor profile of:

John H. Sampson

City:

Durham, North Carolina

Country:

United States

Published Applications:

Last publication date:

2022-12-22

Top Assignees for applications by John H. Sampson

The entities that hold a legal rights for patent applications filed by inventor Sampson John H.:

DUKE UNIVERSITY 27 Durham, NC United States
Board of Regents, The University of Texas System 3 Austin, TX United States
Univeristy of Texas M.D. Anderson Cancer Center 1 Houston, TX United States
Secretary, DHHS 1 Rockville, MD United States

Recent patent applications by Sampson John H.

John H. Sampson from Durham, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2022-12-22

US20220401552A1

Human necessities

Compositions, Methods and Kits for Eliciting an Immune Response

#2 | 2022-12-08

US20220387582A1

Human necessities

Compositions, Methods and Kits for Eliciting an Immune Response

#3 | 2022-12-01

US20220378906A1

Human necessities

Compositions, methods and kits for eliciting an immune response

#4 | 2022-11-24

US20220370602A1

Human necessities

Compositions, Methods and Kits for Eliciting an Immune Response

#5 | 2022-10-27

US20220339223A1

Human necessities

Oncolytic poliovirus for human tumors

#6 | 2022-02-03

US20220031827A1

Human necessities

Tetanus toxoid and CCL3 improve DC vaccines

#7 | 2021-10-07

US20210309750A1

Chemistry; metallurgy

Enhanced Delivery of Drugs and Other Compounds to the Brain and Other Tissues

#8 | 2021-01-07

US20210000944A1

Human necessities

Compositions, methods and kits for eliciting an immune response

#9 | 2021-01-07

US20210000943A1

Human necessities

Compositions, methods and kits for eliciting an immune response

#10 | 2020-12-31

US20200405795A1

Human necessities

Oncolytic poliovirus for human tumors

#11 | 2020-11-05

US20200345837A1

Human necessities

Compositions, methods and kits for eliciting an immune response

#12 | 2020-08-06

US20200246452A1

Human necessities

Compositions, methods and kits for eliciting an immune response

#13 | 2019-11-14

US20190343904A1

Human necessities

Oncolytic poliovirus for human tumors

#14 | 2019-04-11

US20190105360A1

Human necessities

Sequential anti-cancer treatment

#15 | 2018-08-23

US20180236054A1

Human necessities

Tetanus toxoid and CCL3 improve DC vaccines

#16 | 2018-08-02

US20180215789A1

Chemistry; metallurgy

Concurrent Chemotherapy and Immunotherapy

#17 | 2018-06-07

US20180153982A1

Human necessities

Compositions, methods and kits for eliciting an immune response

#18 | 2017-08-03

US20170216382A1

Human necessities

Oncolytic poliovirus for human tumors

#19 | 2016-09-22

US20160271240A1

Human necessities

Tetanus toxoid and CCL3 improve DC vaccines

#20 | 2016-07-28

US20160213771A1

Human necessities

Compositions, methods and kits for eliciting an immune response

#21 | 2016-02-04

US20160030497A1

Human necessities

ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS

#22 | 2015-11-26

US20150335732A1

Human necessities

Compositions, methods, and kits for eliciting an immune response

#23 | 2015-10-29

US20150307614A1

Chemistry; metallurgy

Enhanced immunological responses

#24 | 2015-04-30

US20150118181A1

Chemistry; metallurgy

Concurrent Chemotherapy and Immunotherapy

#25 | 2013-07-25

US20130189224A1

Human necessities

Compositions, methods, and kits for eliciting an immune response

#26 | 2012-11-15

US20120288473A1

Human necessities

Compositions, methods, and kits for eliciting an immune response

#27 | 2012-09-27

US20120244145A1

Chemistry; metallurgy

ENHANCED IMMUNOLOGICAL RESPONSES

#28 | 2012-07-26

US20120189630A1

Chemistry; metallurgy

Bispecific EGFRvIII x CD3 antibody engaging molecules

#29 | 2012-05-10

US20120115739A1

Physics

Assay for anti-EGFRvIII antibodies

#30 | 2011-06-09

US20110135637A1

Human necessities

TRIMODAL CANCER THERAPY

#31 | 2009-09-03

US20090220551A1

Chemistry; metallurgy

Concurrent chemotherapy and immunotherapy

InventorID:

353570 ⎘